Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis

Murtaza M Tambuwala; Mohammed Naeem Khan; Paul Thompson; P. A. McCarron

doi:10.1007/s13346-018-00597-9

Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis

Murtaza M Tambuwala, Mohammed Naeem Khan, Paul Thompson, P. A. McCarron

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

86 Downloads (Pure)

Abstract

Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poor
bioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.

Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.

Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulate
inflammation related biomolecular pathways. Hence, combining nanotechnology with
natural compounds could result in development of new therapeutic options for IBD.

Original language	English
Pages (from-to)	14-24
Number of pages	11
Journal	Drug Delivery and Translational Research
Volume	9
Early online date	14 Nov 2018
DOIs	https://doi.org/10.1007/s13346-018-00597-9
Publication status	Published (in print/issue) - 15 Feb 2019

Keywords

nanoparticles
inflammation
colitis
hypoxia
nuclear factor kappa beta
albumin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13346-018-00597-9Licence: CC BY

Final published versionFinal published version, 2.44 MBLicence: CC BY

Cite this

@article{a0cb12d7479f4de386488a7feac3a8ae,

title = "Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis",

abstract = "Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poorbioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulateinflammation related biomolecular pathways. Hence, combining nanotechnology withnatural compounds could result in development of new therapeutic options for IBD.",

keywords = "nanoparticles , inflammation , colitis, hypoxia, nuclear factor kappa beta, albumin",

author = "Tambuwala, {Murtaza M} and Khan, {Mohammed Naeem} and Paul Thompson and McCarron, {P. A.}",

year = "2019",

month = feb,

day = "15",

doi = "10.1007/s13346-018-00597-9",

language = "English",

volume = "9",

pages = "14--24",

journal = "Drug Delivery and Translational Research",

issn = "2190-393X",

publisher = "Springer",

}

Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis. / Tambuwala, Murtaza M; Khan, Mohammed Naeem; Thompson, Paul et al.
In: Drug Delivery and Translational Research, Vol. 9, 15.02.2019, p. 14-24.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis

AU - Tambuwala, Murtaza M

AU - Khan, Mohammed Naeem

AU - Thompson, Paul

AU - McCarron, P. A.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poorbioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulateinflammation related biomolecular pathways. Hence, combining nanotechnology withnatural compounds could result in development of new therapeutic options for IBD.

AB - Hypoxia inducible factor and nuclear factor kappa beta pathways have been proposed as therapeutic targets for several inflammatory diseases. Caffeic acid phenethyl ester (CAPE) and piceatannol (PIC), are natural anti-inflammatory compounds however, poorbioavailability and limited understanding of biomolecular mechanistic limits its clinical use. The aims of this study are to enhance bioavailability and investigate their impact on nuclear p65 and HIF-1α for the first time in experimental colitis.Dextran sulphate sodium was used to induce colitis in mice and effect of either free CAPE/ PIC or CAPE/PIC loaded albumin nanoparticles treatment was observed on disease development and levels of cellular p65 and HIF-1α.Our results indicate that albumin nano-encapsulation of CAPE / PIC not only enhances its anti-inflammatory potential but also potentiates its ability to effectively modulateinflammation related biomolecular pathways. Hence, combining nanotechnology withnatural compounds could result in development of new therapeutic options for IBD.

KW - nanoparticles

KW - inflammation

KW - colitis

KW - hypoxia

KW - nuclear factor kappa beta

KW - albumin

UR - https://pure.ulster.ac.uk/en/publications/albumin-nano-encapsulation-of-caffeic-acid-phenethyl-ester-and-pi

UR - https://link.springer.com/article/10.1007/s13346-018-00597-9

U2 - 10.1007/s13346-018-00597-9

DO - 10.1007/s13346-018-00597-9

M3 - Article

SN - 2190-393X

VL - 9

SP - 14

EP - 24

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

ER -

Albumin nano-encapsulation of caffeic acid phenethyl ester and piceatannol potentiated its ability to modulate HIF and NF-kB pathways and improves therapeutic outcome in experimental colitis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Caffeic acid phenethyl ester (CAPE) reverses fibrosis caused by chronic colon inflammation in murine model of colitis.

Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function

Cite this